C Chandra Kumar

Summary

Affiliation: Schering-Plough Research Institute
Country: USA

Publications

  1. ncbi Chloramine T-induced structural and biochemical changes in echistatin
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    FEBS Lett 429:239-48. 1998
  2. ncbi SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Ann N Y Acad Sci 886:122-31. 1999
  3. ncbi Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Cancer Res 61:2232-8. 2001
  4. ncbi Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Biochim Biophys Acta 1526:257-68. 2001
  5. ncbi Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis
    C Chandra Kumar
    Department of Tumor Biology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Curr Drug Targets 4:123-31. 2003
  6. ncbi AKT crystal structure and AKT-specific inhibitors
    Chandra C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Oncogene 24:7493-501. 2005
  7. ncbi Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice
    Amanda Jetzt
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Cancer Res 63:6697-706. 2003
  8. ncbi Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase
    Zhuomei Lu
    Department of Tumor Biology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Biomol Screen 9:309-21. 2004
  9. ncbi Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor
    Ahmed A Samatar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Biol Chem 277:28118-26. 2002

Collaborators

Detail Information

Publications9

  1. ncbi Chloramine T-induced structural and biochemical changes in echistatin
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    FEBS Lett 429:239-48. 1998
    ..These structural changes in echistatin help explain the changes in the binding characteristics of the molecule following chloramine T reaction...
  2. ncbi SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Ann N Y Acad Sci 886:122-31. 1999
    ....
  3. ncbi Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Cancer Res 61:2232-8. 2001
    ..Finally, SCH 221153 exerted a significant inhibition on tumor growth induced by intradermal or s.c. injection of human melanoma LOX cells in severe combined immunodeficient mice...
  4. ncbi Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling
    C C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Biochim Biophys Acta 1526:257-68. 2001
    ..However, the ATP binding regions are highly conserved in the three isoforms of Akt implying that the discovery of isoform-selective inhibitors would be very challenging...
  5. ncbi Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis
    C Chandra Kumar
    Department of Tumor Biology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    Curr Drug Targets 4:123-31. 2003
    ..Thus alphavbeta3 may prove to be an important target for pharmacological intervention in more than one clinical setting...
  6. ncbi AKT crystal structure and AKT-specific inhibitors
    Chandra C Kumar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    Oncogene 24:7493-501. 2005
    ..The issues and challenges facing the development of different classes of inhibitors as therapeutics are also discussed...
  7. ncbi Adenoviral-mediated expression of a kinase-dead mutant of Akt induces apoptosis selectively in tumor cells and suppresses tumor growth in mice
    Amanda Jetzt
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    Cancer Res 63:6697-706. 2003
    ..These studies validate the usefulness of targeting Akt for new drug discovery efforts and suggest that inhibition of Akt may have a selective antitumor effect...
  8. ncbi Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase
    Zhuomei Lu
    Department of Tumor Biology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA
    J Biomol Screen 9:309-21. 2004
    ..This coupled assay has the potential to identify compounds that target the inactive form of Akt and prevent its activation by PDK1, in addition to finding inhibitors of PDK1 and activated Akt enzymes...
  9. ncbi Transforming growth factor-beta 2 is a transcriptional target for Akt/protein kinase B via forkhead transcription factor
    Ahmed A Samatar
    Department of Tumor Biology, Schering Plough Research Institute, Kenilworth, New Jersey 07033, USA
    J Biol Chem 277:28118-26. 2002
    ..These results suggest that repression of TGF-beta 2 promoter activity in cells expressing activated Akt may play a role in promoting tumorigenesis and escape from the growth-inhibitory and/or apoptotic effects of TGF-beta...